secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001493152-23-008708
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow reports FY22 revenue $88.6M (+22% YoY), core net income positive; guides FY23 rev $135-143M, adj EBITDA $44-50M
--------------------------------------------------------------------------------

- Full-year 2022 revenues $88.6M, up 22% from $72.5M; core net income $1.5M vs loss of $4.4M in 2021.
- Q4 2022 core EPS $0.07 diluted, vs loss ($0.12) in Q4 2021; GAAP net income $1.1M.
- Reaffirms 2023 guidance: net revenues $135M-$143M, Adjusted EBITDA $44M-$50M.
- FDA-approved IHEEZO received permanent J-Code and pass-through reimbursement; launch expected May 2023.
- Sold non-ophthalmology assets; acquired U.S. rights to five branded ophthalmic products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315223008708/0001493152-23-008708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315223008708/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-008708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer